Home / Congress Presentations / IC-MPGN and C3G / American Society of Nephrology (ASN) Kidney Week 2023
Landing
American Society of Nephrology (ASN) Kidney Week 2023
Phase 3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Treatment of C3G or IC-MPGN
Efficacy and safety of 12-week pegcetacoplan in kidney transplant recipients with recurrent C3G or primary IC-MPGN: 12-week results from the NOBLE study
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.